Maia Chakerian
Pain Medicine · Los Gatos, CANPI 1598708778
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,523 of the $20,680 with a category attached, or 60.6%. 37 manufacturers reported payments, led by Vertex at 43.3% of the total. Among pain medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 199 payments — averaging $103.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$9K
- GRT US Holding, Inc.$4K
- AbbVie$1K
- Trevena, Inc.$1K
- Boston Scientific$758
- Collegium Pharmaceutical, Inc.$756
- plus $4K from 31 others
Across 132 payments — averaging $1606.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$127K
- Seikagaku Corporation$63K
- GRT US Holding, Inc.$22K
- Hikma Pharmaceuticals USA$125
- Purdue Pharma L.p.$125
- Endo Pharmaceuticals Inc.$114
What the payments were for
- Consulting fees$70%
- Speaking & faculty fees$12,52361%
- Travel & lodging$1,1956%
- Food & beverage$6,95534%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 15 | $8,955 |
| GRT US Holding, Inc. | 4 | $4,168 |
| AbbVie(2 entities) | 26 | $1,185 |
| Trevena, Inc. | 1 | $1,000 |
| Boston Scientific | 19 | $758 |
| Collegium Pharmaceutical, Inc. | 37 | $756 |
| Teva Pharmaceuticals USA, Inc. | 13 | $537 |
| Biohaven Pharmaceuticals, Inc. | 12 | $505 |
| Merz North America, Inc. | 6 | $445 |
| Amgen | 9 | $242 |
| Sun Pharmaceutical Industries Inc. | 1 | $195 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $182 |
| Stimwave Technologies Incorporated | 1 | $180 |
| Vertiflex, Inc. | 5 | $147 |
| Indivior Inc. | 2 | $143 |
| AstraZeneca | 1 | $125 |
| Radius Health, Inc. | 1 | $125 |
| Mayne Pharma Commercial LLC | 1 | $125 |
| Abbott | 3 | $109 |
| Lundbeck LLC | 3 | $90 |
| Biodelivery Sciences International, Inc. | 5 | $85 |
| Scilex Pharmaceuticals Inc. | 4 | $85 |
| Lilly USA, LLC | 4 | $73 |
| Novartis | 3 | $62 |
| Pfizer | 2 | $55 |
| Tersera Therapeutics LLC | 2 | $53 |
| Sentynl Therapeutics, Inc. | 4 | $52 |
| Nalu Medical, Inc. | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $32 |
| Si-bone, Inc. | 1 | $29 |
| Merz Pharmaceuticals, LLC | 1 | $25 |
| Nevro Corp. | 1 | $23 |
| Medline Industries LP | 1 | $22 |
| Saluda Medical Americas, Inc. | 1 | $20 |
| Saol Therapeutics Inc. | 1 | $20 |
| Redhill Biopharma Inc. | 1 | $19 |
| Kaleo, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JOURNAVX$8,580
- Qutenza$4,000
- Olinvyk$1,000
- UBRELVY$473
- NURTEC ODT$401
- QULIPTA$371
- AJOVY$352
- GENERAL PAIN MANAGEMENT$259
- XEOMIN$200
- CEQUA$195
- FASENRA$125
- Tymlos$125
- NEXTSTELLIS$125
- SUBLOCADE$125
- GENERAL - THERAPIES$110
How this compares
$20,680 in reported general payments places this provider in the 90th percentile of 840 pain medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 15 | $18,743 |
| Nucynta ErTapentadol Hcl | 11 | $15,489 |
| Xtampza ErOxycodone Myristate | 11 | $9,377 |
| Fentanyl | 60 | $8,292 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 111 | $5,291 |
| Oxycodone Hcl | 55 | $2,151 |
| Hydromorphone Hcl | 48 | $1,938 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 31 | $981 |
| Morphine Sulfate ErMorphine Sulfate | 20 | $847 |
| Duloxetine Hcl | 20 | $614 |
| Gabapentin | 20 | $589 |
| Clonidine Hcl | 14 | $460 |
| Celecoxib | 19 | $439 |
| Tizanidine Hcl | 20 | $198 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta Er, Xtampza Er | $756 | $24,86722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 840 pain medicine providers in California.
Other pain medicine in Los Gatos
- Jason PopeSanta Rosa$2.1M
- Ramana NaiduLarkspur$1.4M
- Foead GeulaStudio City$1.3M
- Krishnan ChakravarthyTemecula$1.3M
- Kasra AmirdelfanWalnut Creek$783K
- Eric GrigsbyNapa$499K
- Jacqueline WeisbeinNapa$494K
- Gerald SacksSanta Monica$389K
- Samir ShethRoseville$356K
- Einar OttestadStanford$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.